Validated HPTLC Method for Simultaneous Estimation of Isotretinoin and Erythromycin in Bulk Drug and Topical Gel Form

Atul S. Rathore, L. Sathiyanarayanan, K. R. Mahadik

.

DOI: 10.4236/ajac.2010.13018                

Abstract

A simple, precise and accurate high performance thin layer chromatographic method has been developed for the simultaneous estimation of Isotretinoin and Erythromycin in pharmaceutical gel. The separation was carried out on Merck TLC aluminum sheets of silica gel 60 F254, (20 × 10 cm) with 250 µm thickness using toluene: DMSO: methanol (6.5:0.2:2.5, v/v/v) as a mobile phase. HPTLC separation of the two drugs followed by densitometric measurement of their spots at 340 nm for Isotretinoin before derivatization and 410 nm for Erythromycin after derivatization with 10% H2SO4 and heating at 100°C for 15 min. The drugs were satisfactorily resolved with RF values of 0.38 ± 0.02 and 0.55 ± 0.02 for Isotretinoin and Erythromycin, respectively. The accuracy and reliability of the method was assessed by evaluation of linearity (30-150 ng spot-1 for Isotretinoin and 1200-6000 ng spot-1 for Erythromycin), precision (intra-day RSD 0.62-0.79% and inter-day RSD 0.43-0.71 % for Isotretinoin and intra-day RSD 0.47-1.71 % and inter-day RSD 0.42-1.49 % for Erythromycin), accuracy (98.91 ± 0.92 % for Isotretinoin and 99.27 ± 0.72 % for Erythromycin), and specificity, in accordance with ICH guidelines.

Keywords

Isotretinoin, Erythromycin, HPTLC, Validation

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. B. Sporn, N. M. Dunlop, D. L. Newton and J. M. Smith, “Prevention of Chemical Carcinogenesis by Vitamin A and Its Synthetic Analogs (Retinoids),” Federation Proceedings, Vol. 35, No. 6, 1976, pp. 1332-1338.
[2]	L. R. Harisiadis, R. C. Miller, E. J. Hall and C. Borek, “A Vitamin A Analogue Inhibits Radiation-Induced Oncogenic Transformation,” Nature, Vol. 274, No. 5670, August 1978, pp. 486-487.
[3]	R. Lotan, “Effects of Vitamin A and Its Analogs (Retinoids) on Normal and Neoplastic Cells,” Biochimica et Biophysica Acta, Vol. 605, No. 1, March 1980, pp. 33-91.
[4]	M. B. Sporn and A. B. Roberts, “What is a Retinoid?” Ciba Foundation Symposium, Vol. 113, 1985, pp. 1-5.
[5]	S. Nagpal, J. Athanikar and R. A. S. Chandraratna, “Separation of Transactivation and AP1 Antagonism Functions of Retinoic Acid Receptor,” Journal of Biological Chemistry, Vol. 270, No. 2, January 1995, pp. 923-927.
[6]	R. A. S. Chandraratna, “Tazarotene—First of a New Generation of Receptor-Selective Retinoids,” British Journal of Dermatology, Vol. 135, No. 49, October 1996, pp. 18-25.
[7]	B. Amichai, A. Shemer and M. Grunwald, “Low-Dose Isotretinoin in the Treatment of Acne Vulgaris,” Journal of the American Academy of Dermatology, Vol. 54, No. 4, April 2006, pp. 644-646.
[8]	C. Mims, H. M. Dockrell, R. V. Goering, I. Roitt, D. Wakelin and M. Zuckerman, “Attacking the Enemy: Antimicrobial Agents and Chemotherapy: Macrolides,” Medical Microbiology, 3rd Edition, Mosby Ltd, London, 2004, p. 489.
[9]	A. Trevor, B. G. Katzung and S. Masters, “Chemotherapeutic Drugs: Chloramphenicol, Tetracyclines, Macrolides, Clindamycin, & Streptogramins,” Pharmacology, 9th Edition, McGraw-Hill Medical, New York, December 2003, pp. 758-759.
[10]	B. M. Tashtoush, E. L. Jacobson and M. K. Jacobson, “A Rapid HPLC Method for Simultaneous Determination of Tretinoin and Isotretinoin in Dermatological Formulations,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 43, No. 3, February 2007, pp. 859-864.
[11]	N. Takeda and A. Yamamoto, “Simultaneous Determination of 13-Cis- and All-Trans-Retinoic Acids and Retinol in Human Serum by High-Performance Liquid Chromatography,” Journal of Chromatography B, Vol. 657, No. 1, July 1994, 53-59.
[12]	B. Disdier, H. Bun, J. Catalin and A. Durand, “Simultaneous Determination of All-Trans-, 13-Cis-, 9-Cis-Retinoic Acid and Their 4-Oxo-Metabolites in Plasma by High-Performance Liquid Chromatography,” Journal of Chromatography B, Vol. 683, No. 2, August 1996, pp. 143-154.
[13]	B. Liawruangrath and S. Liawruangrath, “High Performance Thin Layer Chromatographic Determination of Erythromycin in Pharmaceutical Preparations,” Chromatographia, Vol. 54, No. 5, September 2001, pp. 405-408.
[14]	Y. Kato, T. Yokoyama, M. Shimokawa, K. Kudo, J. Kabe and K. Mohri, “Determination of Erythromycin in Human Plasma and Whole Blood by High-Performance Liquid Chromatography,” Journal of Liquid Chromatography, Vol. 16, No. 3, February 1993, pp. 661-680.
[15]	K. Tsuji and M. P. Kane, “Improved High-Performance Liquid Chromatographic Assay of Erythromycin in Pharmaceutical Solid Dosage Forms,” Journal of Pharmaceutical Sciences, Vol. 71, No. 10, October 1982, pp. 1160- 1164.
[16]	P. Dehouck, E. Van Looy, E. Haghedooren, K. Deckers, Y. Vander Heyden, E. Adams, E. Roets and J. Hoogmartens, “Analysis of Erythromycin and Benzoylperoxide in Topical Gels by Liquid Chromatography,” Journal of Chromatography B, Vol. 794, No. 2, September 2003, pp. 293-302.
[17]	C. Stubbs and I. Kanfer, “High-Performance Liquid Chromatography of Erythromycin Propionyl Ester and Erythromycin Base in Biological Fluids,” Journal of Chromatography: Biomedical Applications, Vol. 427, 1988, pp. 93-101.
[18]	J. Wardrop, D. Ficker, S. Franklin and R. J. Gorski, “Determination of Erythromycin and Related Substances in Enteric-Coated Tablet Formulations by Reversed-Phase Liquid Chromatography,” Journal of Pharmaceutical Sciences, Vol. 89, No. 9, July 2000, pp. 1097-1105.
[19]	ICH Q2 (R1), “Validation of Analytical Procedures: Text and Methodology,” International Conference on Harmonization, Complementary Guideline on Methodology, Geneva, November 2005.